Absorption, metabolism, and excretion of [<sup>14</sup>C]YY-20394, a highly selective PI3K-Delta inhibitor in humans-Reference-Cited by-同舟云学术

Absorption, metabolism, and excretion of [¹⁴C]YY-20394, a highly selective PI3K-Delta inhibitor in humans

Published:2022-03-04 Issue:3 Volume:52 Page:254-264
ISSN:0049-8254
Container-title:Xenobiotica
language:en
Short-container-title:Xenobiotica

Author:

Yu Jinghua¹,Zhang Hua²³,Zhang Yifan¹,Zhan Yan¹,Ma Sheng²³,Hu Tao¹,Zhang Ning¹,Lou Yangtong⁴,Bao Hanying⁴,Xu Zusheng⁴,Zhong Dafang¹,Miao Liyan²³,Diao Xingxing¹

Affiliation:

1. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

2. Department of Pharmacology, the First Affiliated Hospital of Soochow University, Suzhou, China

3. Institute for Interdisciplinary Drug Research and Translational Sciences, Soochow University, Suzhou, China

4. Shanghai Yingli Pharmaceutical Co., Ltd, Shanghai, China

Funder

Shanghai Yingli Pharmaceutical Co., Ltd.

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00498254.2022.2062581

Reference27 articles.

1. Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy

2. Targeting PI3K/AKT/mTOR network for treatment of leukemia

3. Mass Balance Studies, with a Focus on Anticancer Drugs

4. Umbralisib: First Approval

5. FDA US 2020. Safety testing of drug metabolites guidance for industry. [accessed 2020 30 April 2020]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-testing-drug-metabolites.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, Mass Balance and Metabolism of [14C]HSK21542, a Novel Kappa Opioid Receptor Agonist, in Humans;European Journal of Drug Metabolism and Pharmacokinetics;2023-10-13

2. Regulation of Eukaryotic Translation Initiation Factor 4E as a Potential Anticancer Strategy;Journal of Medicinal Chemistry;2023-09-19

3. Pharmacokinetics, Mass Balance, Tissue Distribution, and Metabolism of [3H]Catalpol in Rats: the Main Bioactive Component of Rehmannia glutinosa for the Treatment of Ischemic Stroke;Current Drug Metabolism;2023-06

4. The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial;Clinical Cancer Research;2023-02-03

5. Absorption, distribution, metabolism, and excretion of [14C]Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats;Cancer Chemotherapy and Pharmacology;2022-10-25